Bridges Investment Counsel Inc. reduced its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 73.3% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 2,225 shares of the medical research company’s stock after selling 6,110 shares during the period. Bridges Investment Counsel Inc.’s holdings in Thermo Fisher Scientific were worth $421,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Eqis Capital Management Inc. grew its position in Thermo Fisher Scientific by 5.6% during the 3rd quarter. Eqis Capital Management Inc. now owns 14,391 shares of the medical research company’s stock worth $2,723,000 after purchasing an additional 768 shares during the period. Perigon Wealth Management LLC grew its position in Thermo Fisher Scientific by 1.3% during the 2nd quarter. Perigon Wealth Management LLC now owns 31,251 shares of the medical research company’s stock worth $5,457,000 after purchasing an additional 397 shares during the period. Intl Fcstone Inc. acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth about $276,000. Griffin Asset Management Inc. acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth about $209,000. Finally, Gs Investments Inc. acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth about $3,260,000. 83.78% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/bridges-investment-counsel-inc-has-421000-holdings-in-thermo-fisher-scientific-inc-tmo/1699655.html.

In other Thermo Fisher Scientific news, VP Peter E. Hornstra sold 3,894 shares of the stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $185.18, for a total value of $721,090.92. Following the completion of the sale, the vice president now owns 19,751 shares in the company, valued at approximately $3,657,490.18. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jim P. Manzi sold 11,318 shares of the stock in a transaction dated Friday, August 18th. The shares were sold at an average price of $172.94, for a total transaction of $1,957,334.92. Following the completion of the sale, the director now owns 38,757 shares of the company’s stock, valued at approximately $6,702,635.58. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,738 shares of company stock valued at $4,021,512. 0.49% of the stock is owned by insiders.

Several equities research analysts have weighed in on TMO shares. Cowen and Company reaffirmed an “outperform” rating and set a $220.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Sunday, September 10th. Leerink Swann increased their price target on Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a research report on Monday, October 9th. Zacks Investment Research downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Goldman Sachs Group, Inc. (The) started coverage on Thermo Fisher Scientific in a research report on Tuesday, September 26th. They set a “buy” rating and a $225.00 price target on the stock. Finally, Deutsche Bank AG set a $226.00 price target on Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Thursday, October 26th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $205.71.

Thermo Fisher Scientific Inc (NYSE TMO) opened at $186.18 on Monday. The firm has a market cap of $74,657.32, a PE ratio of 20.46, a P/E/G ratio of 1.71 and a beta of 1.08. Thermo Fisher Scientific Inc has a 12 month low of $139.07 and a 12 month high of $201.20. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.24 by $0.07. The firm had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. Thermo Fisher Scientific’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same period last year, the company posted $2.03 EPS. equities analysts anticipate that Thermo Fisher Scientific Inc will post 9.36 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be issued a $0.15 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a yield of 0.32%. Thermo Fisher Scientific’s payout ratio is 10.19%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.